Registry of long-term antithrombotic therapy for atrial fibrillation
Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation
This study looks at how safe and effective long-term blood-thinning treatments are for people with atrial fibrillation by tracking any complications they might have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Government |
| Locations | 1 site (Moscow) |
| Trial ID | NCT04347187 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the rates of ischemic and hemorrhagic complications associated with long-term antithrombotic therapy in patients diagnosed with atrial fibrillation. Conducted at a single center in Russia, the study will involve patients who meet specific criteria for antithrombotic treatment. By documenting outcomes over time, the study seeks to provide insights into the safety and efficacy of anticoagulants in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with documented atrial fibrillation and a CHA2DS2VASC score greater than 1.
Not a fit: Patients who are unwilling or unable to provide informed consent or have severe comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the risks associated with long-term antithrombotic therapy, potentially leading to improved treatment strategies for patients with atrial fibrillation.
How similar studies have performed: Other studies have explored antithrombotic therapy in atrial fibrillation, indicating that this approach has been previously tested, though the specific focus on long-term outcomes in this registry may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented atrial fibrillation with CHA2DS2VASC \> 1 Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention
Where this trial is running
Moscow
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation — Moscow, Russia (Recruiting)
Study contacts
- Principal investigator: Elizaveta Panchenko, PhD — National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Study coordinator: Ekaterina Kropacheva, PhD
- Email: katekrab@list.ru
- Phone: +79166760695
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.